STOCK TITAN

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

TransMedics Group (Nasdaq: TMDX) announced the granting of inducement awards to 6 new employees on October 23, 2024. The grants include 2,969 non-qualified stock options with an exercise price of $118.66 per share and 1,937 restricted stock units. The stock options will vest 25% after one year, with the remainder vesting monthly over three years. The restricted stock units will vest 25% annually over four years. Both grants require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

TransMedics Group (Nasdaq: TMDX) ha annunciato il conferimento di premi di inducimento a 6 nuovi dipendenti il 23 ottobre 2024. I premi includono 2.969 opzioni su azioni non qualificate con un prezzo d'esercizio di $118,66 per azione e 1.937 azioni vincolate. Le opzioni su azioni matureranno il 25% dopo un anno, mentre il resto maturerà mensilmente nel corso di tre anni. Le azioni vincolate matureranno il 25% annualmente per quattro anni. Entrambi i premi richiedono l'impiego continuativo e sono stati approvati dal Comitato Compensi secondo la Regola 5635(c)(4) del Nasdaq.

TransMedics Group (Nasdaq: TMDX) anunció la concesión de premios de inducimiento a 6 nuevos empleados el 23 de octubre de 2024. Las concesiones incluyen 2,969 opciones sobre acciones no calificadas con un precio de ejercicio de $118.66 por acción y 1,937 unidades de acciones restringidas. Las opciones sobre acciones se consolidarán al 25% después de un año, con el resto consolidándose mensualmente durante tres años. Las unidades de acciones restringidas se consolidarán al 25% anualmente durante cuatro años. Ambas concesiones requieren empleo continuo y fueron aprobadas por el Comité de Compensación bajo la Regla de Listado 5635(c)(4) del Nasdaq.

TransMedics Group (Nasdaq: TMDX)는 2024년 10월 23일에 6명의 새로운 직원에게 유도 상여금을 수여한다고 발표했습니다. 수여된 상여금에는 2,969개의 비적격 주식 옵션과 주당 $118.66의 행사 가격, 1,937개의 제한 주식 단위가 포함됩니다. 주식 옵션은 1년 후 25%가 행사되며, 나머지는 3년 동안 월별로 행사됩니다. 제한 주식 단위는 4년 동안 매년 25%가 행사됩니다. 두 상여금 모두 지속적인 고용이 필요하며, Nasdaq 상장 규칙 5635(c)(4)에 따라 보상 위원회의 승인을 받았습니다.

TransMedics Group (Nasdaq: TMDX) a annoncé le 23 octobre 2024 l'octroi de primes d'incitation à 6 nouveaux employés. Les primes comprennent 2 969 options d'achat d'actions non qualifiées avec un prix d'exercice de 118,66 $ par action et 1 937 unités d'actions restreintes. Les options d'achat d'actions acquerront 25 % après un an, le reste s'acquérant mensuellement sur une période de trois ans. Les unités d'actions restreintes acquerront 25 % annuellement sur quatre ans. Les deux octrois nécessitent un emploi continu et ont été approuvés par le Comité de Rémunération selon la règle de cotation 5635(c)(4) du Nasdaq.

TransMedics Group (Nasdaq: TMDX) gab am 23. Oktober 2024 die Gewährung von Anreizpremien für 6 neue Mitarbeiter bekannt. Die Gewährungen umfassen 2.969 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von $118,66 pro Aktie und 1.937 eingeschränkte Aktienanteile. Die Aktienoptionen werden nach einem Jahr zu 25% fällig, während der Rest über drei Jahre monatlich fällig wird. Die eingeschränkten Aktienanteile werden jährlich zu 25% über einen Zeitraum von vier Jahren fällig. Beide Gewährungen erfordern eine fortlaufende Beschäftigung und wurden vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.

Positive
  • None.
Negative
  • None.

ANDOVER, Mass., Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 2,969 shares of its common stock and an aggregate of 1,937 restricted stock units to 6 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

TransMedics granted non-qualified stock options to purchase 2,969 shares of TransMedics' common stock and 1,937 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $118.66, the closing price of the common stock on the Nasdaq Global Market on October 23, 2024. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the Company through the applicable vesting date. The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.

About TransMedics Group, Inc. 
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302290516.html

SOURCE TransMedics Group, Inc.

FAQ

What inducement grants did TransMedics (TMDX) announce on October 23, 2024?

TransMedics announced granting 2,969 non-qualified stock options at $118.66 per share and 1,937 restricted stock units to 6 new employees.

What is the vesting schedule for TransMedics (TMDX) October 2024 stock options?

The stock options vest 25% after the first year, with the remaining amount vesting in equal monthly installments over the following three years, subject to continued employment.

How do the restricted stock units vest in TransMedics (TMDX) October 2024 inducement grants?

The restricted stock units vest 25% annually over four years, subject to continued employment with TransMedics.

TransMedics Group, Inc.

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Stock Data

2.65B
32.48M
3.18%
111.8%
25.11%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ANDOVER